Setmelanotide emerges as key pharmacologic intervention for hypothalamic obesity, targeting `MC4R` pathway amidst complex management challenges.
Pharmacologic and Non-Pharmacologic Interventions for Hypothalamic Obesity: An Updated Review.
Abstract
Setmelanotide, an MC4R agonist, is a newly FDA-approved pharmacologic intervention for hypothalamic obesity management.